PRES-like leukoencephalopathy presenting with status epilepticus associated with Brentuximab Vedotin treatment

Acta Biomed. 2022 Mar 21;92(S4):e2021416. doi: 10.23750/abm.v92iS4.12665.

Abstract

Posterior Reversible Encephalopathy Syndrome (PRES) is characterized by acute neurological symptoms with typical imaging features, primarily in the territories of the brain supplied by the posterior circulation, probably due to vasogenic edema. Both clinical and imaging features are generally reversible. We report a 13-year-old girl affected by Nodular Sclerosis Classical Hodgkin Lymphoma stage IIIB into complete remission, with a recurrence and autologous bone-marrow transplantation, who has been treated with an anti-CD30 monoclonal antibody, brentuximab-vedotin. The girl has suddenly presented a convulsive status epilepticus, that needed intubation and sedation. Therefore, an IV therapy with levetiracetam was started. Furthermore, the girl has presented high blood pressure and reduced kidney function. Brain MRI demonstrated a diffuse PRES-like disease, that went into regression after the first week. After another week, the girl presented a new prolonged generalized tonic clonic convulsive episode, that needed intubation and sedation and an association of clobazam and levetiracetam: a new brain MRI showed a recurrence of PRES-like lesions in addition to some signs of leukoencephalopathy with brain lactate accumulation on 1H-MRS, due to cerebral energetic failure. The girl also presented a refractory arterial hypertension. After 45 days of ICU hospitalization the patient has been discharged and followed up with neurological examinations. Brain MRI and brain 1H-MRS, 5 months after patient's discharge, showed incomplete regression of cerebral white matter signal abnormalities with MRS normalization.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Brentuximab Vedotin
  • Female
  • Humans
  • Hypertension* / complications
  • Levetiracetam / therapeutic use
  • Magnetic Resonance Imaging / methods
  • Posterior Leukoencephalopathy Syndrome* / chemically induced
  • Status Epilepticus* / complications
  • Status Epilepticus* / etiology

Substances

  • Levetiracetam
  • Brentuximab Vedotin